Tag Archives: ATNM

Sunday’s Highlights at Noon: Xoma (XOMA), Peabody Energy Comm (BTU), EKSO BIONICS (EKSO), Actinium Pharmaceuticals (ATNM), Arena Pharma (ARNA)

So far Sunday, June 27, NASDAQ is down -0.09% and the S&P is up 0.69%. Here are this morning’s most active stocks: Xoma (XOMA – Research Report), Peabody Energy Comm (BTU – Research Report), EKSO BIONICS (EKSO – Research Report),

Saturday’s Midday Movers: Xoma (XOMA), Peabody Energy Comm (BTU), EKSO BIONICS (EKSO), Actinium Pharmaceuticals (ATNM), Arena Pharma (ARNA)

So far Saturday, June 26, NASDAQ is down -0.09% and the S&P is up 0.69%. Here are this morning’s most active stocks: Xoma (XOMA – Research Report), Peabody Energy Comm (BTU – Research Report), EKSO BIONICS (EKSO – Research Report),

Monday’s Midday Movers: Renesola (SOL), Fuelcell Energy (FCEL), Intercept Pharma (ICPT), Actinium Pharmaceuticals (ATNM), 3D Systems (DDD)

So far Monday, May 24, NASDAQ is up 0.35% and the S&P is up 2.38%. Here are this morning’s most active stocks: Renesola (SOL – Research Report), Fuelcell Energy (FCEL – Research Report), Intercept Pharma (ICPT – Research Report), Actinium

Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 13 and set a price target of $65.00. The company’s shares closed last Tuesday at $8.06. According to TipRanks.com, Pantginis is a

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (NYSE MKT: ATNM) and Codiak BioSciences (NASDAQ: CDAK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) and Codiak BioSciences (CDAK – Research Report) with bullish sentiments. Actinium Pharmaceuticals (ATNM) William Blair analyst

Actinium Pharmaceuticals (ATNM) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $65.00. The company’s shares closed last Friday at $10.84. According to TipRanks.com, Pantginis is